Evidence map›Paper›PMID 34379445›Full record

ReviewAnnual review of medicine2022

Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies.

Kazunori Omote, Frederik H Verbrugge, Barry A Borlaug

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annual review of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06486649 (Application of a Multimodal Large Language Model to Assist Diagnosis for Heart Failure With Preserved Ejection Fraction), which is not on this map. Cited by 126 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06486649 unknown statusnot on this mapstarted 2023, after this paper: background citation

Application of a Multimodal Large Language Model to Assist Diagnosis for Heart Failure With Preserved Ejection Fraction

TypeobservationalSponsorPeking University Third HospitalRan2023 to 2024Enrolled80ConditionsHeart Failure With Preserved Ejection FractionArmsMultimodal Large Language Model Diagnosis, Routine diagnostic and therapeutic procedure
3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Nutrients · 2026
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kazunori OmoteDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA; email: borlaug.barry@mayo.edu.
Frederik H VerbruggeDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA; email: borlaug.barry@mayo.edu.
Barry A BorlaugDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA; email: borlaug.barry@mayo.edu.

Funding

HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection FractionR01HL128526 · NHLBI · MAYO CLINIC ROCHESTER · PI BORLAUG, BARRY A. · 2016 to 2019
$2.4M
NHLBI NIH HHS R01 HL128526
6 · The paper itself

Abstract

Approximately half of all patients with heart failure (HF) have a preserved ejection fraction, and the prevalence is growing rapidly given the aging population in many countries and the rising prevalence of obesity, diabetes, and hypertension. Functional capacity and quality of life are severely impaired in heart failure with preserved ejection fraction (HFpEF), and morbidity and mortality are high. In striking contrast to HF with reduced ejection fraction, there are few effective treatments currently identified for HFpEF, and these are limited to decongestion by diuretics, promotion of a healthy active lifestyle, and management of comorbidities. Improved phenotyping of subgroups within the overall HFpEF population might enhance individualization of treatment. This review focuses on the current understanding of the pathophysiologic mechanisms underlying HFpEF and treatment strategies for this complex syndrome.

Indexed as

Heart FailureAgedComorbidityHumansQuality of LifeStroke VolumeVentricular Function, Leftheart failureheart failure with preserved ejection fractionpathophysiologytreatment

Identifiers

PMID34379445
PMCPMC9002335

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.